BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35294484)

  • 21. Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer.
    Kim HJ; Lee YM; Ko BS; Lee JW; Yu JH; Son BH; Gong GY; Kim SB; Ahn SH
    Ann Surg Oncol; 2011 Jul; 18(7):1830-6. PubMed ID: 21573699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer.
    Peterson DJ; Truong PT; Sadek BT; Alexander CS; Wiksyk B; Shenouda M; Raad RA; Taghian AG
    Ann Surg Oncol; 2014 Oct; 21(11):3490-6. PubMed ID: 24841346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The effect of axillary lymph node status on the prognosis of patients with local-regional recurrence after breast-conserving surgery].
    Zhang Z; Zhang W; Li ZJ; Wang XM; Cao XC; Xiao CH
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):347-351. PubMed ID: 29860761
    [No Abstract]   [Full Text] [Related]  

  • 25. Breast-conserving surgery without axillary lymph node surgery or radiotherapy is safe for HER2-positive and triple negative breast cancer patients over 70 years of age.
    Zhong Y; Xu Y; Zhou Y; Mao F; Lin Y; Guan J; Shen S; Pan B; Wang C; Peng L; Huang X; Li Y; Wang X; Sun Q
    Breast Cancer Res Treat; 2020 Jul; 182(1):117-126. PubMed ID: 32430680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes.
    Wang H; Yao J; Zhu Y; Zhan W; Chen X; Shen K
    Cancer Med; 2020 Sep; 9(17):6173-6185. PubMed ID: 32657039
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
    Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
    Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survival analysis according to period and analysis of the factors influencing changes in survival in patients with recurrent breast cancer: a large-scale, single-center study.
    Lee SB; Sohn G; Kim J; Chung IY; Lee JW; Kim HJ; Ko BS; Son BH; Ahn SH
    Breast Cancer; 2018 Nov; 25(6):639-649. PubMed ID: 29786773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metaplastic breast cancer: clinicopathological features and its prognosis.
    Lee H; Jung SY; Ro JY; Kwon Y; Sohn JH; Park IH; Lee KS; Lee S; Kim SW; Kang HS; Ko KL; Ro J
    J Clin Pathol; 2012 May; 65(5):441-6. PubMed ID: 22412048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
    Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
    J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Her-2 prognostic value in very early-stage breast cancer: a single-institution retrospective analysis.
    Sanpaolo P; Barbieri V; Pedicini P; Fusco V
    Med Oncol; 2012 Jun; 29(2):459-65. PubMed ID: 21359639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
    Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
    Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Long-term survival analysis of different breast cancer molecular subtypes: Shanghai Breast Cancer Survival Study].
    Bao P; Peng P; Gu K; Wu C; Huang Z; Gong Y; Zhang M; Zheng Y
    Zhonghua Wai Ke Za Zhi; 2015 Dec; 53(12):928-34. PubMed ID: 26850665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX.
    Metzger-Filho O; Sun Z; Viale G; Price KN; Crivellari D; Snyder RD; Gelber RD; Castiglione-Gertsch M; Coates AS; Goldhirsch A; Cardoso F
    J Clin Oncol; 2013 Sep; 31(25):3083-90. PubMed ID: 23897954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
    Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
    Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 37. Prevalence and clinical outcomes of young breast cancer (YBC) patients according to intrinsic breast cancer subtypes: Single institutional experience in Korea.
    Park YH; Lee SJ; Jung HA; Kim SM; Kim MJ; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
    Breast; 2015 Jun; 24(3):213-7. PubMed ID: 25728283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].
    Chen SY; Tang Y; Song YW; Wang SL; Jin J; Liu YP; Wang WH; Fang H; Ren H; Sun GY; Wang JY; Jing H; Zhang JH; Liu XF; Yu ZH; Li YX
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):619-625. PubMed ID: 30139034
    [No Abstract]   [Full Text] [Related]  

  • 39. Survival time according to the year of recurrence and subtype in recurrent breast cancer.
    Nakano M; Fujisue M; Tashima R; Okumura Y; Nishiyama Y; Ohsako T; Toyozumi Y; Arima N; Nishimura R
    Breast; 2015 Oct; 24(5):588-93. PubMed ID: 26099804
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer recurrence according to molecular subtype.
    Shim HJ; Kim SH; Kang BJ; Choi BG; Kim HS; Cha ES; Song BJ
    Asian Pac J Cancer Prev; 2014; 15(14):5539-44. PubMed ID: 25081661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.